Clinical Trials Listing

Clinical Trials Listing

The following are the currently Active Clinical Trials as of 11/7/2009 5:11:25 AM.

To send email regarding a particular Clinical Trial, click on the underlined Nurse's name.

*Breast*	Top
*Also see Solid Tumor*

Protocol Number	Title	Principal Investigator	Nurse Contact	Phone
ECOG E5103	A Double-Blind, Phase III Trial of Doxorubicin and Cyclosphosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive or High Risk Node Negative Breast Cancer	Falkson	Caterinicchia, Valerie, RN, BSN	(205) 934-5367

ECOG PACCT 1	Program for the Assessment of Clinical Cancer Tests (PACCT-1) Trial Assigning Individualized Options for Treatment: The TAILORx Trial	Falkson	Wilson, Robyn RN	(205) 975-6347

ECOG S0307	Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer	Falkson	Caterinicchia, Valerie, RN, BSN	(205) 934-5367

IBCSG 2402	A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane Adjuvant Therapies for Premenopausal Women with Endocrine Responsive Breast Cancer (SOFT Trial)	Falkson	Caterinicchia, Valerie, RN, BSN	(205) 934-5367

RTOG 0413	A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer	Meredith	Oldham, Latania RN	(205) 975-2880

RTOG 0517	Randomized Phase III Trial to Evaluate Radiopharmaceutical and Zoledronic Acid in the Palliation of Osteoblastic Metastases from Lung, Breast, and Prostate Cancer	Meredith	Oldham, Latania RN	(205) 975-2880

UAB 0493	Phase II Trial of Primary Systemic Therapy for Locally Advanced Breast Cancer using Sequential Doxil, Paclitaxel and Cyclophosphamide with Concurrent Avastin	Carpenter	Wilson, Robyn RN	(205) 975-6347

UAB 0648	A Phase II, Randomized, Open Label Trial of Pre-Operative (Neoadjuvant) Letrozole (Femara) vs. Letrozole in Combination with Avastin in Post-Menopausal Women with Newly Diagnosed Operable Breast Cancer	Forero-Torres	Wilson, Robyn RN	(205) 975-6347

UAB 0762	Phase II Study of Lapatinib in Combination with Tastuzumab in Patients with HER2-Positive, Metastatic Breast Cancer	Falkson	Wilson, Robyn RN	(205) 975-6347

UAB 0763	A Phase II Trial of Lapatinib and Trastuzumab with or without Endocrine Therapy in Locally Advanced HER2 Overexpressing Breast Cancer Patients	Forero-Torres	Wilson, Robyn RN	(205) 975-6347

UAB 0778	MPA Revisited: A Phase II Study of Anti-Metastic, Anti-Angiogenic Therapy in Postmenopausal Patients with Hormone Recptor Negative Breast Cancer	Nabell	Wilson, Robyn RN	(205) 975-6347

UAB 0813	A Multicenter Phase III, Randomized Trial of Adjuvant Therapy for Patients with HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Plus Trastuzumab Plus Bevacizumab	Falkson	Caterinicchia, Valerie, RN, BSN	(205) 934-5367

UAB 0836	A Randomized, Multicenter, Phase II Study of the Efficacy and Safety of Trastuzumab-MCC-DM1 vs. Trastuzumab (Herceptin) and Docetaxel (Taxotere) in Patients with Metastatic HER-2 Positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic Disease	Nabell	Caterinicchia, Valerie, RN, BSN	(205) 934-5367

UAB 0905	A Phase I/II Study of R1507 with Letrozole for Postmenopausal Women with ER+ HER2 - Advanced Breast Cancer	Carpenter	Caterinicchia, Valerie, RN, BSN	(205) 934-5367

UAB 0909	A Phase II Study of Cisplatin or Carboplatin for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response	Forero-Torres	Caterinicchia, Valerie, RN, BSN	(205) 934-5367

*Breast Cancer Prevention*	Top

Protocol Number		Title		Principal Investigator		Nurse Contact		Phone
UAB 0413		A Phase III Randomized Study of Exemestane vs. Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer		Krontiras		Richardson, Joey RN		(205) 975-0450

*Cervix*	Top
*Also see Solid Tumor*

Protocol Number		Title		Principal Investigator		Nurse Contact		Phone
GOG 219		Phase III, Randomized Trial of Weekly Cisplatin and Radiation vs. Cisplatin and Tirapazamine and Radiation in Stage IB2, IIA, IIB, IIIB and IVA Cervical Carcinoma Limited to the Pelvis		Barnes		Jones, Laura RN		(205) 930-8646

*Colon*	Top
*Also see Solid Tumor*

Protocol Number		Title		Principal Investigator		Nurse Contact		Phone
ECOG E5202		A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers		Falkson		Carlisle, Ronda RN, BSN		(205) 975-2511

*Head and Neck*	Top
*Also see Solid Tumor*

Protocol Number	Title	Principal Investigator	Nurse Contact	Phone
RAD 0503	Phase III Trial of Erlotinib and Radiotherapy in Patients with Stage III Cutaneous Squamous Cell Carcinomas	Rosenthal	Oldham, Latania RN	(205) 975-2880

RTOG 0619	A Randomized Phase II Trial of Chemoradiotherapy Versus Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck	Meredith	Oldham, Latania RN	(205) 975-2880

UAB 0718	Phase II Trial to Assess Target Oral Therapy as Adjuvant Chemoprevention in High-Risk Head and Neck Cancer	Rosenthal	Clemons, Lisa RN	(205) 934-9714

UAB 0749	GEN205 - An Open Label, Single Arm Trial Investigating Zalutumumab, a Human Monoclonal Anti-EGF Receptor Antibody, in Combination with Best Supportive Care in Patients with Non-Curable Squamous Cell Carcinoma of the Head and Neck and Who Have Failed Standard Platinum-Based Chemotherapy	Rosenthal	Clemons, Lisa RN	(205) 934-9714

*Hematologic*	Top

Protocol Number	Title	Principal Investigator	Nurse Contact	Phone
CALGB 10603	A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/Cytarabine) Chemotherapy + Midostaurin (PKC412) or Placebo in Newly Diagnosed Patients < 60 Years of Age with FLT3 Mutated Acute Myeloid Leukemia (AML)	Falkson	Valdmanis, Amy R. RN, BSN, OCN	(205) 975-9481

UAB 0624	Standarization of CD3+ T-Cell Dose for Patients Receiving Allogeneic Peripherial Blood Hematopoietic Stem Cell Transplants from Matched Related Donors	Vaughan	Williams, Lisa RN	(205) 934-0066

UAB 0657	A Phase I/IIa Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of AT9283, a Small Molecule Inhibitor of Aurora Kinases, in Patients with Acute Leukemia, Chronic Myeloid Leukemia, High-Risk Myelodysplastic Syndromes or Myelofibrosis	Foran	Connor, Jeanne RN, OCN	(205) 975-2944

UAB 0663	Open Label, One Arm Pilot Investigation of Lenalidomide (Revlimid) Therapy for Patients with Relapsed and/or Refractory Peripheral T-Cell Lymphomas	Foran	Valdmanis, Amy R. RN, BSN, OCN	(205) 975-9481

UAB 0757	An Open-Label, Phase Ib Study of the Safety, Pharmacokinetics and Activity of the Anti-CD40 Monoclonal Antibody SGN-40 Administered in Combination with Rituximab in Patients with CD20-Positive Follicular and Marginal Zone B-Cell Non-Hodgkin's Lymphoma Who Have Relapsed Following Previous Rituximab	Forero-Torres	Connor, Jeanne RN, OCN	(205) 975-2944

UAB 0758	A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy (Rituximab, Ifosfamide, Carboplatin, and Etoposide) with and wihthout SGN-40 (anti-CD40 humanized monoclonal antibody) for Second-Line Treatment of Patients with Diffuse Large B-Cell Lymphoma	Forero-Torres	Valdmanis, Amy R. RN, BSN, OCN	(205) 975-9481

UAB 0822	A Randomized Phase II Study of Oral Sapacitabine in Elderly Patients with Acute Myeloid Leukemia Previously Untreated or in First Relapse, or Previously Treated Myelodysplastic Syndrome	Foran	Valdmanis, Amy R. RN, BSN, OCN	(205) 975-9481

UAB 0823	A Phase I Safety Study of LY2127399 in Combination with Bortezomib in Patients with Relapsed or Refractory Multiple Myeloma	Forero-Torres	Valdmanis, Amy R. RN, BSN, OCN	(205) 975-9481

UAB 0824	Phase I/II Study of Immunotherapy with Milatuzumab (hLL1) in Patients with Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (Protocol 102)	Forero-Torres	Connor, Jeanne RN, OCN	(205) 975-2944

UAB 0830	Trubion Protocol - A Phase I/II Study of TRU-016 in Paients with Previously Treated Chronic Lymphocytic Leukemia	Forero-Torres	Valdmanis, Amy R. RN, BSN, OCN	(205) 975-9481

UAB 0845	A Phase III, Randomized, Open-Label, 3-Arm Study to Determine the Efficacy and Safety of Lenalidomide (Revlimid) Plus Low-Dose Dexamethasone When Given Until Progressive Disease or for 18 Four-Week Cycles Versus the Combination of Melphalan, Prednisone, and Thalidomide Given for 12 Six-Week Cycles in Patients with Previously Untreated Multiple Myeloma Who Are Either 65 Years of Age or Older or Not Candidates for Stem Cell Transplantation	Foran	Valdmanis, Amy R. RN, BSN, OCN	(205) 975-9481

UAB 0853	A Phase 2 Study of SGN-35 in Treatment of Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma (ALCL)	Forero-Torres	Connor, Jeanne RN, OCN	(205) 975-2944

UAB 0916	An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212 in Subjects with Relapsed or Refractory Leukemias	Foran	Connor, Jeanne RN, OCN	(205) 975-2944

*Hypopharynx*	Top
*Also see Solid Tumor*

Protocol Number		Title		Principal Investigator		Nurse Contact		Phone
UAB 0718		Phase II Trial to Assess Target Oral Therapy as Adjuvant Chemoprevention in High-Risk Head and Neck Cancer		Rosenthal		Clemons, Lisa RN		(205) 934-9714

*Kidney*	Top
*Also see Solid Tumor*

Protocol Number	Title	Principal Investigator	Nurse Contact	Phone
ECOG E2804	The BeST Trial: A Randomized Phase II Study of VEGF, RAF Kinase, and mTor Combination Targeted Therapy (CTT) with Bevacizumab, Sorafenib and Temsirolimus in Advanced Renal Cell Carcinoma	Falkson	Carlisle, Ronda RN, BSN	(205) 975-2511

ECOG E2805	A Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib versus Sorafenib versus Placebo in Patients with Resected Renal Cell Carcinoma	Falkson	Carlisle, Ronda RN, BSN	(205) 975-2511

*Larynx*	Top
*Also see Solid Tumor*

Protocol Number		Title		Principal Investigator		Nurse Contact		Phone
UAB 0718		Phase II Trial to Assess Target Oral Therapy as Adjuvant Chemoprevention in High-Risk Head and Neck Cancer		Rosenthal		Clemons, Lisa RN		(205) 934-9714

*Leukemia*	Top

Protocol Number	Title	Principal Investigator	Nurse Contact	Phone
CALGB 10603	A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/Cytarabine) Chemotherapy + Midostaurin (PKC412) or Placebo in Newly Diagnosed Patients < 60 Years of Age with FLT3 Mutated Acute Myeloid Leukemia (AML)	Falkson	Valdmanis, Amy R. RN, BSN, OCN	(205) 975-9481

UAB 0657	A Phase I/IIa Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of AT9283, a Small Molecule Inhibitor of Aurora Kinases, in Patients with Acute Leukemia, Chronic Myeloid Leukemia, High-Risk Myelodysplastic Syndromes or Myelofibrosis	Foran	Connor, Jeanne RN, OCN	(205) 975-2944

UAB 0822	A Randomized Phase II Study of Oral Sapacitabine in Elderly Patients with Acute Myeloid Leukemia Previously Untreated or in First Relapse, or Previously Treated Myelodysplastic Syndrome	Foran	Valdmanis, Amy R. RN, BSN, OCN	(205) 975-9481

UAB 0824	Phase I/II Study of Immunotherapy with Milatuzumab (hLL1) in Patients with Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (Protocol 102)	Forero-Torres	Connor, Jeanne RN, OCN	(205) 975-2944

UAB 0830	Trubion Protocol - A Phase I/II Study of TRU-016 in Paients with Previously Treated Chronic Lymphocytic Leukemia	Forero-Torres	Valdmanis, Amy R. RN, BSN, OCN	(205) 975-9481

UAB 0916	An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212 in Subjects with Relapsed or Refractory Leukemias	Foran	Connor, Jeanne RN, OCN	(205) 975-2944

*Liver*	Top
*Also see Solid Tumor*

Protocol Number		Title		Principal Investigator		Nurse Contact		Phone
UAB 0844		A Phase III Randomized, Double-Blind, Placebo-Controlled Study of Sorafenib as Adjuvant Treatment for Hepatocellular Carcinoma after Surgical Resection or Local Ablation		Posey		Craig, Dayle RN		(205) 975-8080

*Lung*	Top
*Also see Solid Tumor*

Protocol Number	Title	Principal Investigator	Nurse Contact	Phone
CALGB 30506	A Randomized Phase III Trial of Adjuvant Therapy in Early Stage Non-Small Cell Lung Cancer Evaluating the Potential Utility of a Genomic Prognostic Model to Identify Patients as Candidates for Adjuvant Chemotherapy	Cerfolio	Rawlins, Ashlee Brooke RN	(205) 996-7361

RTOG 0517	Randomized Phase III Trial to Evaluate Radiopharmaceutical and Zoledronic Acid in the Palliation of Osteoblastic Metastases from Lung, Breast, and Prostate Cancer	Meredith	Oldham, Latania RN	(205) 975-2880

RTOG 0617	A Randomized Phase III Comparison of Standard-Dose (60 Gy) Versus High-Dose (74 Gy) Conformal Radiotherapy with Concurrent and Consolidation Carboplatin/Paclitaxel +/- Cetuximab in Patients with Stage IIIA/IIIB Non-Small Cell Lung Cancer	Meredith	Oldham, Latania RN	(205) 975-2880

UAB 0476	Randomized Phase III Study of Docetaxel or Pemetrexed with or without Cetuximab in Patients with Recurrent or Progressive Non-Small Cell Lung Cancer after Platinum-Based Therapy	Robert	Messer, Anna RN	(205) 934-5092

UAB 0649	Phase I Feasibility Study of the Combination of Fondaparinux (Arixtra) with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer	Robert	Dillard, Wilma RN	(205) 975-9289

UAB 0707	A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Single-Agent Tarceva (erlotinib) Following Complete Tumor Resection and With or Without Adjuvant Chemotherapy in Patients with Stage IB-IIIA Non-Small Cell Lung Carcinoma who have EGFR-Positive Tumors	Cerfolio	Calloway, Sandra G. RN	(205) 934-5937

UAB 0709	Pilot Phase II Study of Metronomic Chemotherapy in Combination with Avastin in Patients with Advanced Non-Small Cell Lung Cancer	Robert	Messer, Anna RN	(205) 934-5092

UAB 0750	Pilot Phase IIa Study of Metronomic Chemotherapy with Taxotere (Docetaxel) plus Nexvar (Sorafenib) as First Line Therapy in Performance Status 2 Patients with Advanced Non-Small Cell Lung Cancer	Robert	Dillard, Wilma RN	(205) 975-9289

UAB 0818	Phase I/IIa Study of the Novel Combination of Bendamustine with Irinotecan Followed by Etoposide/Carboplatin in Chemo Naive Patients with Extensive Stage Small Cell Lung Cancer	Robert	Messer, Anna RN	(205) 934-5092

UAB 0840	Pilot Phase II Study of MORAb-009 Chemotherapy in Combination with Pemetrexed and Cisplatin in Subjects with Mesothelioma	Robert	Dillard, Wilma RN	(205) 975-9289

*Lymphoma*	Top

Protocol Number	Title	Principal Investigator	Nurse Contact	Phone
UAB 0663	Open Label, One Arm Pilot Investigation of Lenalidomide (Revlimid) Therapy for Patients with Relapsed and/or Refractory Peripheral T-Cell Lymphomas	Foran	Valdmanis, Amy R. RN, BSN, OCN	(205) 975-9481

UAB 0757	An Open-Label, Phase Ib Study of the Safety, Pharmacokinetics and Activity of the Anti-CD40 Monoclonal Antibody SGN-40 Administered in Combination with Rituximab in Patients with CD20-Positive Follicular and Marginal Zone B-Cell Non-Hodgkin's Lymphoma Who Have Relapsed Following Previous Rituximab	Forero-Torres	Connor, Jeanne RN, OCN	(205) 975-2944

UAB 0758	A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy (Rituximab, Ifosfamide, Carboplatin, and Etoposide) with and wihthout SGN-40 (anti-CD40 humanized monoclonal antibody) for Second-Line Treatment of Patients with Diffuse Large B-Cell Lymphoma	Forero-Torres	Valdmanis, Amy R. RN, BSN, OCN	(205) 975-9481

UAB 0824	Phase I/II Study of Immunotherapy with Milatuzumab (hLL1) in Patients with Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (Protocol 102)	Forero-Torres	Connor, Jeanne RN, OCN	(205) 975-2944

UAB 0853	A Phase 2 Study of SGN-35 in Treatment of Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma (ALCL)	Forero-Torres	Connor, Jeanne RN, OCN	(205) 975-2944

*Melanoma*	Top
*Also see Solid Tumor*

Protocol Number	Title	Principal Investigator	Nurse Contact	Phone
ECOG E1697	Phase III Randomized Study of Four Weeks High Dose IFN-a2b in Stage T3 - T4 or N1 (microscopic) Melanoma	Falkson	Ross, Teresa RN	(205) 978-2848

ECOG E2602	Phase II Study of Low Dose Peginterferon Alfa-2b in Patients with Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor	Falkson	Ross, Teresa RN	(205) 978-2848

UAB 0829	A Double-Blind, Randomized, Placebo-Controlled, Phase II Study to Assess the Efficacy of recMAGE-A3 + AS15 ASCI as Adjuvant Therapy in Patients with MAGE-A3 Positive Resected Stage III Melanoma	Conry	Ross, Teresa RN	(205) 978-2848

UAB 0904	A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination with Temazolomide vs. Temozolomide Alone in Subjects with Metastatic Melanoma	Conry	Ross, Teresa RN	(205) 978-2848

*Mesothelioma*	Top

Protocol Number		Title		Principal Investigator		Nurse Contact		Phone
UAB 0840		Pilot Phase II Study of MORAb-009 Chemotherapy in Combination with Pemetrexed and Cisplatin in Subjects with Mesothelioma		Robert		Dillard, Wilma RN		(205) 975-9289

*Multiple Myeloma*	Top

Protocol Number	Title	Principal Investigator	Nurse Contact	Phone
UAB 0823	A Phase I Safety Study of LY2127399 in Combination with Bortezomib in Patients with Relapsed or Refractory Multiple Myeloma	Forero-Torres	Valdmanis, Amy R. RN, BSN, OCN	(205) 975-9481

UAB 0845	A Phase III, Randomized, Open-Label, 3-Arm Study to Determine the Efficacy and Safety of Lenalidomide (Revlimid) Plus Low-Dose Dexamethasone When Given Until Progressive Disease or for 18 Four-Week Cycles Versus the Combination of Melphalan, Prednisone, and Thalidomide Given for 12 Six-Week Cycles in Patients with Previously Untreated Multiple Myeloma Who Are Either 65 Years of Age or Older or Not Candidates for Stem Cell Transplantation	Foran	Valdmanis, Amy R. RN, BSN, OCN	(205) 975-9481

*Myelodysplastic Syndrome*	Top

Protocol Number	Title	Principal Investigator	Nurse Contact	Phone
UAB 0657	A Phase I/IIa Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of AT9283, a Small Molecule Inhibitor of Aurora Kinases, in Patients with Acute Leukemia, Chronic Myeloid Leukemia, High-Risk Myelodysplastic Syndromes or Myelofibrosis	Foran	Connor, Jeanne RN, OCN	(205) 975-2944

UAB 0822	A Randomized Phase II Study of Oral Sapacitabine in Elderly Patients with Acute Myeloid Leukemia Previously Untreated or in First Relapse, or Previously Treated Myelodysplastic Syndrome	Foran	Valdmanis, Amy R. RN, BSN, OCN	(205) 975-9481

UAB 0916	An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212 in Subjects with Relapsed or Refractory Leukemias	Foran	Connor, Jeanne RN, OCN	(205) 975-2944

*Oral Cavity*	Top
*Also see Solid Tumor*

Protocol Number		Title		Principal Investigator		Nurse Contact		Phone
UAB 0718		Phase II Trial to Assess Target Oral Therapy as Adjuvant Chemoprevention in High-Risk Head and Neck Cancer		Rosenthal		Clemons, Lisa RN		(205) 934-9714

*Oropharynx*	Top
*Also see Solid Tumor*

Protocol Number		Title		Principal Investigator		Nurse Contact		Phone
UAB 0718		Phase II Trial to Assess Target Oral Therapy as Adjuvant Chemoprevention in High-Risk Head and Neck Cancer		Rosenthal		Clemons, Lisa RN		(205) 934-9714

*Ovary*	Top
*Also see Solid Tumor*

Protocol Number	Title	Principal Investigator	Nurse Contact	Phone
GOG 212	A Randomized Phase III Trial of Maintenace Chemotherapy Comparing 12 Monthly Cycles of Single Agent Paclitaxel or Xyotax (CT-2103) vs. No Treatment until Documented Relapse in Women with Advanced Ovarian or Primary Peritoneal Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy	Barnes	Bagley, Regina RN	(205) 930-8647

GOG 218	A Phase III Trial of Carboplatin and Paclitaxel plus Placebo vs. Carboplatin and Paclitaxel plus Concurrent Bevacizumab Followed by Placebo vs. Carboplatin and Paclitaxel plus Concurrent and Extended Bevacizumab in Women with Newly Diagnosed, Previously Untreated, Stage III (Suboptimal) and All Stage IV Epithelial Ovarian or Primary Peritoneal Cancer	Barnes	Bagley, Regina RN	(205) 930-8647

UAB 0727	A Phase II Protocol of Carboplatin/Gemcitabine + Bevacizumab versus Placebo	Barnes	Gable, JoLane RN	(205) 930-8645

*Pancreas*	Top
*Also see Solid Tumor*

Protocol Number	Title	Principal Investigator	Nurse Contact	Phone
UAB 0601	A Phase 2 Double-Blind, Placebo Controlled, Multi-Center Adjuvant Trial of the Efficacy, Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant Saccharomyces cerevisiae Expressing Mutant Ras Protein Combined with a Gemcitabine Regimen Versus a Gemcitabine Regimen with Placebo, in Patients with Post-Resection R0/R1 Pancreatic Cancer with Tumor Sequence Confirmation of Ras Mutations	Arnoletti	Craig, Dayle RN	(205) 975-8080

UAB 0808	A Phase II Study of Short-Course Preoperative Erlotinib Followed by Post-Operative Erlotinib-Gemcitabine in Patients with Resectable Pancreatic Adenocarcinoma	Arnoletti	Richardson, Joey RN	(205) 975-0450

UAB 0914	A Randomized Phase III Study of Weekly ABI-007 plus Gemcitabine versus Gemcitabine Alone in Patients with Metastatic Adenocarcinoma of the Pancreas	Wood	Craig, Dayle RN	(205) 975-8080

*Prostate*	Top
*Also see Solid Tumor*

Protocol Number	Title	Principal Investigator	Nurse Contact	Phone
RTOG 0517	Randomized Phase III Trial to Evaluate Radiopharmaceutical and Zoledronic Acid in the Palliation of Osteoblastic Metastases from Lung, Breast, and Prostate Cancer	Meredith	Oldham, Latania RN	(205) 975-2880

RTOG 0521	A Phase III Protocol of Androgen Suppression (AS) and 3DCRT/IMRT vs AS and 3DCRT/IMRT Followed by Chemotherapy with Docetaxel and Prednisone for Localized, High-Risk Prostate Cancer	Meredith	Oldham, Latania RN	(205) 975-2880

RTOG 0534	A Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed Only Radiotherapy (Support) in Prostate Cancer Patients with a Rising PSA after Radical	Meredith	Oldham, Latania RN	(205) 975-2880

*Sarcoma*	Top
*Also see Solid Tumor*

Protocol Number	Title	Principal Investigator	Nurse Contact	Phone
UAB 0814	A Pivotal Trial to Determine the Efficacy and Safety of AP23573 when Administered as Maintenance Therapy to Patients with Metastatic Soft-Tissue or Bone Sarcoma	Conry	Ross, Teresa RN	(205) 978-2848

UAB 0850	A Randomized Double-Blind Phase III Trial of Pazopanib versus Placebo in Patients with Soft Tissue Sarcoma Whose Disease has Progressed During or Following Prior Therapy	Conry	Ross, Teresa RN	(205) 978-2848

*Skin*	Top
*Also see Solid Tumor*

Protocol Number		Title		Principal Investigator		Nurse Contact		Phone
RAD 0503		Phase III Trial of Erlotinib and Radiotherapy in Patients with Stage III Cutaneous Squamous Cell Carcinomas		Rosenthal		Oldham, Latania RN		(205) 975-2880

*Solid Tumors*	Top

Protocol Number		Title		Principal Investigator		Nurse Contact		Phone
RAD 0408		Phase II Study of Spinal Radiosurgery		Fiveash		Oldham, Latania RN		(205) 975-2880

*Thyroid*	Top
*Also see Solid Tumor*

Protocol Number		Title		Principal Investigator		Nurse Contact		Phone
UAB 0835		An International, Randomized, Double-Blinded, Phase III Efficacy Study of XL184 versus Placebo in Subjects with Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer		Nabell		Carlisle, Ronda RN, BSN		(205) 975-2511

87 Protocols Listed.